Bristol’s Dealmakers Aim To Avoid 'Innovator’s Dilemma'

In an interview at the J.P. Morgan meeting in January, Bristol’s new head of business development Paul Biondi highlights deals that support the company's aims in diversifying within oncology and beyond it, even as its lead in immuno-oncology grows.